|
a |
|
b/man/data-validateExp.Rd |
|
|
1 |
\name{validateExp} |
|
|
2 |
\alias{validateExp} |
|
|
3 |
\docType{data} |
|
|
4 |
\title{ |
|
|
5 |
Data of the validation drug sensitivity screen using five additional drugs |
|
|
6 |
} |
|
|
7 |
\description{ |
|
|
8 |
|
|
|
9 |
To validate some of the associations observed in the main screen, |
|
|
10 |
including the associations between IGHV status and HSP90 inhibitors |
|
|
11 |
and the associations between trisomy 12 and MEK/ERK pathway inhibitors, |
|
|
12 |
the effect of five additional drugs, cobimetinib (MEK inhibitor), |
|
|
13 |
trametinib (MEK inhibitor), SCH772984 (ERK inhibitor), Ganetespib |
|
|
14 |
(HSP90 inhibitor) and Onalespib (HSP90 inhibitor) were tested on 128 CLL |
|
|
15 |
samples that were also used in the main screen. |
|
|
16 |
|
|
|
17 |
The results were stored in a tidy table (tibble) with four columns: |
|
|
18 |
|
|
|
19 |
1) 'patientID' - The patient identifiers. |
|
|
20 |
|
|
|
21 |
2) 'Drug' - The names of the drugs used in this screen. |
|
|
22 |
|
|
|
23 |
3) 'Concentration' - The concentrations of the drugs in the unit of uM. |
|
|
24 |
|
|
|
25 |
4) 'viab' - Viabilities of the samples after drug treatment, normalized by negative controls (DMSO). |
|
|
26 |
} |
|
|
27 |
\author{Junyan Lu} |
|
|
28 |
\usage{ |
|
|
29 |
validateExp |
|
|
30 |
} |
|
|
31 |
\format{ |
|
|
32 |
Tidy table with 3200 rows and 4 columns. |
|
|
33 |
} |
|
|
34 |
\keyword{datasets} |